Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UQP15 is a preclinical-stage siRNA therapeutic developed by BioGene Therapeutics for the treatment of diabetes and obesity. It utilizes "Smart-siRNA" technology to target and silence the mRNA of Protein Tyrosine Phosphatase 1B (PTP1B), a negative regulator of insulin and leptin signaling. The drug is formulated in bioresponsive lipid nanoparticles (bLNPs) and delivered via an intranasal nose-to-brain spray using a Sol-Gel platform. This delivery method is intended to bypass the blood-brain barrier, allowing the siRNA to modulate metabolic pathways within the central nervous system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UQP15.